|
|
Vaccine Detail
|
HPV DNA Plasmids Therapeutic Vaccine VGX-3100 |
| Vaccine Information |
- Vaccine Name: HPV DNA Plasmids Therapeutic Vaccine VGX-3100
- Target Pathogen: Cancer
- Target Disease: Cancer
- Vaccine Ontology ID: VO_0007448
- Type: DNA vaccine
- Status: Clinical trial
- Host Species for Licensed Use: Human
- Host Species as Laboratory Animal Model: Human
- E7
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- E6
gene engineering:
- Type: Recombinant protein preparation
- Description:
- Detailed Gene Information: Click Here.
- Description: A DNA vaccine consisting of plasmids encoding the E6 and E7 genes of human papilloma virus (HPV) subtypes 16 and 18, respectively, with potential immunostimulating and antineoplastic activities. Administered via intramuscular electroporation, HPV DNA plasmids therapeutic vaccine VGX-3100 expresses E6 and E7 proteins, which may elicit a cytotoxic T-lymphocyte (CTL) response against cervical cancer cells expressing E6 and E7 proteins, resulting in tumor cell lysis. HPV type 16 and HPV type 18 are the most common HPV types involved in cervical carcinogenesis. (NCIT_C77909).
|
| Host Response |
|
|
| References |
NCIT_C77909: [https://ncit.nci.nih.gov/ncitbrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C77909]
|
|
